Literature DB >> 31016576

Biosimilars in the Americas: the future by consensus.

Robert John Moots1.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31016576     DOI： 10.1007/s10067-019-04549-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  2 in total

1.  Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases.

Authors:  Jonathan Kay; Monika M Schoels; Thomas Dörner; Paul Emery; Tore K Kvien; Josef S Smolen; Ferdinand C Breedveld
Journal:  Ann Rheum Dis       Date:  2017-09-02       Impact factor: 19.103

2.  Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab.

Authors:  Joachim Listing; Jörn Kekow; Bernhard Manger; Gerd-Rüdiger Burmester; Dagmar Pattloch; Angela Zink; Anja Strangfeld
Journal:  Ann Rheum Dis       Date:  2013-11-29       Impact factor: 19.103
  2 in total
  1 in total

Review 1.  Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?

Authors:  Eduardo Mysler; Valderilio Feijó Azevedo; Silvio Danese; Daniel Alvarez; Noriko Iikuni; Beverly Ingram; Markus Mueller; Laurent Peyrin-Biroulet
Journal:  Drugs       Date:  2021-10-27       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.